Categories: Health

Ro Weight Loss Announces Official Website Update Featuring Natural Daily Program for Medically-Guided Weight Management

New York, June 07, 2025 (GLOBE NEWSWIRE) —

Ro Weight Loss, a digital health service from Roman Health Ventures Inc., has updated its official website to provide new information about its medically-guided weight management program. Designed for adults across the United States, the offering connects eligible individuals with licensed healthcare providers through a secure telehealth platform.

According to the official website (https://ro.co/weight-loss/), Ro Weight Loss offers a structured approach to weight care, including FDA-approved treatment options when appropriate, along with personalized clinical support and lifestyle guidance. The service is designed to be accessible from home and does not require in-person clinic visits or restrictive dietary regimens.

“We created Ro Weight Loss to make effective, evidence-backed care more accessible,” said a Ro spokesperson. “Our platform empowers people with a personalized plan, clinical oversight, and flexible support tailored to their health goals.”

Ro states that the program prioritizes safety, transparency, and sustainable progress. After completing an online health assessment, users may be evaluated by board-certified providers to determine medical eligibility. When appropriate, providers may prescribe treatment as part of a comprehensive plan that includes coaching and follow-up.

All care is delivered by licensed professionals, and medications are dispensed by U.S.-based pharmacies. The platform supports discreet access to care, ongoing communication with providers, and convenience for users managing their health goals remotely.

The Ro Weight Loss program is currently available in all 50 states. Individuals interested in exploring eligibility or learning more about the service can visit the official website for additional information.

About Ro Weight Loss

Ro Weight Loss is a service provided by Roman Health Ventures Inc., a New York-based telehealth company offering evidence-based treatment across multiple areas of care, including weight management, mental health, dermatology, and more. Ro’s digital platform empowers individuals to receive safe, personalized healthcare from the comfort of home.

Product and Contact Information

Brand: Ro Weight Loss
Website: https://ro.co/weight-loss/
Email: care@ro.co
Mailing Address:
Roman Health Ventures Inc.
625 6th Ave, 4th Floor
New York, NY 10011

Disclaimer

This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The statements made about this program have not been evaluated by the Food and Drug Administration. Individual results may vary. Consumers should consult a qualified healthcare provider before beginning any new treatment plan.

Affiliate Disclosure

This news release contains affiliate links. If you purchase through these links, the publisher may earn a commission at no additional cost to you. This disclosure complies with the Federal Trade Commission’s guidelines on endorsements and testimonials in advertising. All opinions expressed are strictly those of the author or publisher.



GlobeNews Wire

Recent Posts

Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: Ocular Therapeutix, Inc. BEDFORD, Mass., Feb. 06, 2026…

2 hours ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI,…

2 hours ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing…

2 hours ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies

AlUla, Saudi Arabia, Feb. 7, 2026 /PRNewswire/ -- The second edition of the AlUla Conference…

2 hours ago

Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…

2 hours ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

February 06, 2026 17:17 ET  | Source: Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, Feb. 06,…

2 hours ago